Three states in Australia have just agreed to fund a drug which will help protect babies against the effects of RSV, a major cause of respiratory illness in children.
But doctors say New Zealand remains behind the eight ball with no plans in sight for nirsevimab here.
They're calling for urgent access to the drug.
Auckland University Associate Professor and a paediatric infectious disease specialist Emma Best spoke to Corin Dann.
